#	Pagina
attuale pagina	/open-h2020/projects/213691/index.html

Opendata, web and dolomites

DifMATRIX SIGNED

Ground breaking 3D cell culture platform to eliminate animal testing in pharmaceuticals

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

DifMATRIX project word cloud

Explore the words cloud of the DifMATRIX project. It provides you a very rough idea of what is the project "DifMATRIX" about.

globally extremely saving global behave inomatrix overcomes simulated letters continues billion trials efficiency vitro 2d cancer 3d experimentation commercialisation significantly fail models phenotype ethical translation culture biology 85 medical animal raises supplies passive clinical human supplier predicted 28 inocure cell confirmed consequence simulate medications preclinical drug customers 8 bodies tissue life 2020 natural difmatrix time standards market living vivo demand intent prospective molecular cultures cells platform prices despite alternative environment witnessing engineering redefines biopharmaceuticals scaffolding successful costly rates aligned launch practical eliminate

Project "DifMATRIX" data sheet

The following table provides information about the project.

Coordinator	INOCURE SRO Organization address address: POLITICKYCH VEZNU 935/13 city: PRAHA postcode: 11000 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Czech Republic [CZ]
Project website	http://www.inocure.cz/
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT)) 2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
Code Call	H2020-SMEINST-1-2016-2017
Funding Scheme	SME-1
Starting year	2018
Duration (year-month-day)	from 2018-03-01 to 2018-08-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	INOCURE SRO INOCURE SRO Organization address address: POLITICKYCH VEZNU 935/13 city: PRAHA postcode: 11000 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	CZ (PRAHA)	coordinator	50˙000.00

Map

Project objective

The use of in-vitro testing (in simulated environment) is the future of drug development, cancer research and medical research in general since it overcomes the practical and ethical issues associated with human and animal experimentation. However, as much as 85% of early clinical trials currently fail despite successful preclinical in-vitro testing; in the case of clinical cancer trials it is less than 8%. The main reason for such low success rates is that currently used 2D cells do not behave the same in living bodies as in cultures. As a consequence, animal testing continues to be widespread despite the associated cost and strong ethical concerns it raises. This is also extremely costly in time and resources which raise consumer prices for life-saving medications. InoCure is addressing this problem with the DifMATRIX - a unique 3D scaffolding platform with drug delivery embedded system, for cell culture used in molecular biology and tissue engineering. DifMATRIX enables to simulate natural cell phenotype (in vivo) in the in-vitro environment. It redefines in-vitro preclinical testing standards, significantly improving preclinical-to-clinical translation efficiency and provide an alternative to animal testing models. The predicted impact of the project is to eliminate the animal testing phase from the drug development process. The project is well aligned with new trends in cell and tissue culture supplier market. Globally, this market is witnessing significant growth due to increasing demand for biopharmaceuticals and increasing R&D in this field. The global cell/tissue engineering supplies market is expected to reach $28 billion in 2020. The market demand for DifMATRIX has been confirmed by customers currently using our passive InoMATRIX product, and by the letters of intent from prospective customers. Following the proposed Phase 1, Inocure target is to apply for the Phase 2 project to scale-up the production and launch commercialisation of DifMATRIX.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DIFMATRIX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DIFMATRIX" are provided by the European Opendata Portal: CORDIS opendata.